ArticleInternational journal of transgender health2026
Persistent menstruation in transgender people using testosterone gender-affirming hormone therapy.
Article in International journal of transgender health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Changes in Hormone Cycles and Exercise Capacity During Testosterone Therapy in a Transmasculine Triathlete: A Case Study.Exercise, sport & movement · 2027Article
- Efficacy of Fixed Low-Dose Weekly Subcutaneous Testosterone Self-Administration in Transgender Male Patients in India.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The cessation of menstruation is a common and desired outcome of testosterone gender-affirming hormone therapy (GAHT), for trans and gender diverse (collectively referred to as trans) individuals recorded female at birth. This study aimed to (a) assess the prevalence and characteristics of menstruation before and after commencing testosterone GAHT, and (b) explore factors associated with persistent menstruation. Method: Trans people using testosterone therapy for gender affirmation, aged ≥16 years and living in Australia completed an online cross-sectional survey between 28 August to 31 December 2020. Multivariable logistic regression analysis was applied to estimate the effect size of factors potentially contributing to the cessation or persistence of menstruation 6 months after starting testosterone therapy. Results: There were 401 eligible respondents. Median age for commencement of testosterone GAHT was 23 years (IQR = 20, 28) and the median duration of testosterone therapy was 37 months (IQR = 19, 65). Intramuscular testosterone undecanoate injections were the most used formulation. Persistent menstruation >6 months after commencing testosterone GAHT was reported by 87 (22.8%) participants. The odds of reporting persistent menstruation >6 months after commencing testosterone were (a) higher in people using testosterone gels/creams compared to testosterone injections (OR = 11.3 [1.1, 118.2]), and (b) lower in individuals with a body mass index ≥30 kg/m Conclusion: Persistent menstruation >6 months after commencing testosterone GAHT may be impacted by body mass index and the mode of testosterone administration. This is important information for individuals considering testosterone GAHT as well as for clinicians advising on the benefits and drawbacks of different forms of testosterone administration as well as the likelihood of menstrual cessation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.